Brain Mechanisms Underlying the Effect of the Motilin Receptor Agonist Erythromycin on Hunger in Normal Weight Subjects

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02212821

Enrollment

Registered

2014-08-08

Start date

2014-09-30

Completion date

Unknown

Last updated

2016-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Brief summary

The purpose of this study is to investigate the role of erythromycin, a prokinetic agent, on hunger, and the brain mechanism lying behind it.

Interventions

DRUGErythromycin

DRUGPlacebo

physiological saline

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Female only. * Age \> 18 and \< 60. * Body Mass Index (BMI) of 19-25 kg/m2 (no weight change of more than 5 kg in the past three months). * Not known to have any chronic medical illness or illnesses affecting the gastrointestinal, cardiovascular, or nervous systems, chronic pain or psychiatric disorder. * If female not known to be pregnant. * Not known to have any past upper gastrointestinal surgery.

Exclusion criteria

* Alcohol consumption \> 7 drinks / week * Major depression and chronic health conditions except controlled hypertension

Design outcomes

Primary

Measure	Time frame	Description
Functional brain images	40 min after intervention	The functional brain images will be taken via functional magnetic resonance imaging (fMRI), and be analysed via a software called SPM.

Secondary

Measure	Time frame	Description
hunger scores	every 10 minutes since the scan starts	The hunger scores will be taken every 10 minutes since the scan starts via a 10 cm visual analogue scale.
gut hormones	every 10 min since the scan starts	Peripheral blood samples will be taken every 10 min since the scan starts until the endpoint of the study to measure gut hormones (motilin, ghrelin, CCK, PYY, GLP-1) by radioimmuno-assay.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026